Research Topics
| B K DunnSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Epigenetics in cancer prevention: early detection and risk assessment: introductionBarbara K Dunn
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Executive Plaza North, Rockville, Maryland 20852-7362, USA
Ann N Y Acad Sci 983:1-4. 2003
Selenium and prostate cancer prevention: insights from the selenium and vitamin E cancer prevention trial (SELECT)Holly L Nicastro
Cancer Prevention Fellowship Program, Nutritional Science Research Group, Division of Cancer Prevention, National Cancer Institute, 9609 Medical Center Dr, Rockville, MD 20850, USA
Nutrients 5:1122-48. 2013....- Biomarkers as surrogate endpoints in cancer trialsBarbara K Dunn
National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
Semin Oncol Nurs 28:99-108. 2012.... - Molecular markers for early detectionBarbara K Dunn
National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892 7340, USA
Semin Oncol 37:224-42. 2010.... - Health disparities in breast cancer: biology meets socioeconomic statusBarbara K Dunn
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892 7340, USA
Breast Cancer Res Treat 121:281-92. 2010..We will attempt to clarify some of the issues, including risk factors, in terms of their contribution to that component of health disparities that involves biological differences in breast cancer between women of AA and white women... - A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)Barbara K Dunn
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
Nutr Cancer 62:896-918. 2010..07, P = 0.16) were observed. SELECT data show that neither selenium nor vitamin E, alone or together, in the doses and formulations used, prevented prostate cancer in this heterogeneous population of healthy men... - Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunitiesBarbara K Dunn
Basic Prevention Science Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892 7340, USA
Recent Results Cancer Res 188:21-47. 2011.... - Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulatorsBarbara K Dunn
US National Cancer Institute, Division of Cancer Prevention, USA
Ann N Y Acad Sci 1155:141-61. 2009..The Study of Letrozole and Raloxifene (STELLAR), using as the control raloxifene, the new U.S. standard drug for BC prevention, would complete the trio of AI prevention trials, but STELLAR is currently on hold... - Conclusions: Considerations regarding SERMsB K Dunn
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20852, USA
Ann N Y Acad Sci 949:352-65. 2001..Finally, we explore the process by which statistically meaningful results from clinical trials are extrapolated into the specific drug indications that apply to clinical practice... - Hypomethylation: one side of a larger pictureBarbara K Dunn
Basic Prevention Sciences Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
Ann N Y Acad Sci 983:28-42. 2003..Thus, hypomethylation, in a variety of settings in which it represents a deviation from "normal," appears to correlate with progression to cancer and offers potential mechanisms to explain the carcinogenic process... - The application of genetics and genomics to cancer preventionKathleen Calzone
Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Semin Oncol 37:407-18. 2010..Here, we provide an overview of the scope of genetic and genomic influences on cancer risk assessment and the entire spectrum of cancer prevention... 
Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trialSarah J Nyante
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Rockville, MD 20852, USA
Gynecol Oncol 120:474-9. 2011..We examined relationships between histopathologic diagnoses, false-positive test group, and participant and screening test characteristics...- Landmarks in the history of cancer epidemiologyPeter Greenwald
Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland, USA
Cancer Res 69:2151-62. 2009.... - Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer PreventionMukesh Verma
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852, USA
Ann N Y Acad Sci 983:298-319. 2003..Further research will lead to the identification of new targets for cancer prevention... - Do we make optimal use of the potential of cancer prevention?Peter Greenwald
National Cancer Institute NIH, Division of Cancer Prevention, Bethesda, MD 20892, USA
Recent Results Cancer Res 181:3-17. 2009..Training current researchers in new approaches will add efficiency to their combined research experiences... - Opportunities for future researchS Sherman
National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA
Ann N Y Acad Sci 949:366-74. 2001.... - Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancerTanya Agurs-Collins
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA
Semin Oncol 37:384-401. 2010..We will attempt to clarify some of the issues, in terms of their contribution to that component of health disparities that involves biological differences in breast cancer between women of African ancestry and white women... - Prevention of hormone-related cancers: breast cancerBarbara K Dunn
National Cancer Institute, 6130 Executive Blvd, Room 2046, Bethesda, MD 20892, USA
J Clin Oncol 23:357-67. 2005.... - From adjuvant therapy to breast cancer prevention: BCPT and STARB K Dunn
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
Breast J 7:144-57. 2001..Study endpoints include invasive and noninvasive breast cancer, cardiovascular disease, endometrial cancer, bone fractures, and vascular events... - Hormonal interventions to prevent hormonal cancers: breast and prostate cancersBarbara K Dunn
Basic Prevention Science Research Group bNational Cancer Institute, Division of Cancer Prevention, Deputy Directors Office, Bethesda, Maryland 20892 7309, USA
Eur J Cancer Prev 16:232-42. 2007.... - Influence of genetic background and tissue types on global DNA methylation patternsHoward H Yang
Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
PLoS ONE 5:e9355. 2010..Furthermore, we showed that tissue types are important contributors of DNA methylation states... - Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell linesMitsutaka Kadota
Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
PLoS ONE 5:e9201. 2010.... - Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CAMitsutaka Kadota
Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer Res 69:7357-65. 2009..Our gene amplification and somatic mutation analysis of breast primary tumors provides a coherent picture of genetic events, both corroborating and novel, offering insight into the genetic underpinnings of breast cancer progression...